Does anyone know how many minorities they employ?
George Robinson, had acquired 63,334 shares of company stock between December 14 and December 18 (yesterday) at prices between $3.43 and $3.97 per share. This large insider buy by Robinson comes on the heels of him making another Form 4 filing back on December 11, showing that he had purchased 46,812 shares between December 7 and December 11. This puts Robinson’s holdings of Nymox Pharmaceutical Corp (NASDAQ:NYMX) at 2,532,746 shares of common stock.
Nymox Pharmaceutical Corporation (NYMX) released long-term clinical trial outcome from the Company’s NX-1207 Phase 2 prostate cancer study NX03-0040. The new outcome demonstrate statistically noteworthy (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients contrast to controls. Trial participants comprised of 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.